A. Capron, G. Riveau, M. Capron, and F. Trottein, Schistosomes: the road from host-parasite interactions to vaccines in clinical trials, Trends Parasitol, vol.21, issue.3, p.15734662, 2005.

C. H. King, K. Dickman, and D. J. Tisch, Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis, Lancet, vol.365, issue.9470, pp.1561-1570, 2005.

D. J. Gray, A. G. Ross, Y. S. Li, and D. P. Mcmanus, Diagnosis and management of schistosomiasis, BMJ, vol.342, issue.2651, p.3230106, 2011.

, Schistosomiasis: number of people treated worldwide in 2013, WHO, vol.90, issue.5, p.25638822, 2015.

B. M. Tebeje, M. Harvie, H. You, A. Loukas, and D. P. Mcmanus, Schistosomiasis vaccines: where do we stand? Parasit Vectors, vol.9, p.5045607, 2016.

M. Herve, V. Angeli, E. Pinzar, R. Wintjens, C. Faveeuw et al., Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion, Eur J Immunol, vol.33, issue.10, p.14515260, 2003.

F. Remoue, J. C. Mani, M. Pugniere, A. M. Schacht, A. Capron et al., Functional specific binding of testosterone to Schistosoma haematobium 28-kilodalton glutathione S-transferase, Infect Immun, vol.70, issue.2, p.127730, 2002.

A. Torres-rivera and A. Landa, Glutathione transferases from parasites: a biochemical view, Acta Trop, vol.105, issue.2, p.17897613, 2008.

K. A. Johnson, F. Angelucci, A. Bellelli, M. Herve, J. Fontaine et al., Crystal structure of the 28 kDa glutathione S-transferase from Schistosoma haematobium, Biochemistry, vol.42, issue.34, pp.10084-94, 2003.

D. Boulanger, A. Warter, B. Sellin, V. Lindner, R. J. Pierce et al., Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge, Vaccine, vol.17, issue.4, p.9987169, 1999.

H. M. Dupre, A. M. Schacht, A. Capron, and G. Riveau, Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment, J Infect Dis, vol.180, issue.2, pp.454-63, 1999.

G. Riveau, D. Deplanque, F. Remoue, A. M. Schacht, H. Vodougnon et al., Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis, PLoS Negl Trop Dis, vol.6, issue.7, p.3389022, 2012.

A. X. Mo, J. M. Agosti, J. L. Walson, B. F. Hall, and L. Gordon, Schistosomiasis elimination strategies and potential role of a vaccine in achieving global health goals, Am J Trop Med Hyg, vol.90, issue.1, p.3886428, 2014.

, WHO. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products-Sixth Report. WHO Technical Report Series, vol.3, issue.850, pp.97-137, 1995.

, Guidelines for Good Clinical Practice (3 errata post step 4 included). ICH Harmonised Tripartite Guideline, 1996.

J. M. Balloul, P. Sondermeyer, D. Dreyer, M. Capron, J. M. Grzych et al., Molecular cloning of a protective antigen of schistosomes, Nature, vol.326, issue.6109, p.2434863, 1987.


N. Katz, A. Chaves, and J. Pellegrino, A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni, Rev Inst Med Trop Sao Paulo, vol.14, issue.6, 1972.

A. Ebrahim, H. El-morshedy, O. E. El-daly, S. Barakat, and R. , Evaluation of the Kato-Katz thick smear and formol ether sedimentation techniques for quantitative diagnosis of Schistosoma mansoni infection, Am J Trop Med Hyg, vol.57, issue.6, p.9430532, 1997.

J. Keiser, N. 'guessan, N. A. Adoubryn, K. D. Silue, K. D. Vounatsou et al., Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial, Clin Infect Dis, vol.50, issue.9, pp.1205-1218, 2010.

D. Costa, A. V. Gaubert, S. Lafitte, S. Fontaine, J. Capron et al., Egg-hatching inhibition in mice immunized with recombinant Schistosoma bovis 28 kDa glutathione S-transferase, Parasite Immunol, vol.21, issue.7, p.10417668, 1999.

F. Remoue, F. Rogerie, M. C. Gallissot, H. L. Guyatt, J. L. Neyrinck et al., Sex-dependent neutralizing humoral response to Schistosoma mansoni 28GST antigen in infected human populations, J Infect Dis, vol.181, issue.5, pp.1855-1864, 2000.

R. Akpata, A. Neumayr, M. C. Holtfreter, I. Krantz, D. D. Singh et al., The WHO ultrasonography protocol for assessing morbidity due to Schistosoma haematobium. Acceptance and evolution over 14 years. Systematic review, Parasitol Res, vol.114, issue.4, p.25711148, 2015.

A. Capron, G. J. Riveau, P. B. Bartley, and D. P. Mcmanus, Curr Drug Targets Immune Endocr Metabol Disord, vol.2, p.12476492, 2002.

M. Lebens, J. B. Sun, H. Sadeghi, M. Backstrom, I. Olsson et al., A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection, Vaccine, vol.21, issue.5-6, p.12531651, 2003.

J. B. Sun, N. Mielcarek, M. Lakew, J. M. Grzych, A. Capron et al., Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice, J Immunol, vol.163, issue.2, 1999.

K. M. Mitchell, F. Mutapi, T. Mduluza, N. Midzi, N. J. Savill et al., Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium, PLoS Negl Trop Dis, vol.8, issue.7, p.25079601, 2014.

P. Central and P. , , p.4117464

C. D. Bourke, N. Nausch, N. Rujeni, L. J. Appleby, K. M. Mitchell et al., Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis, J Infect Dis, vol.208, issue.1, p.3666130, 2013.

C. D. Bourke, N. Nausch, N. Rujeni, L. J. Appleby, F. Trottein et al., Cytokine responses to the antischistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatment, PLoS Negl Trop Dis, vol.8, issue.5, p.4014416, 2014.

F. Remoue, T. Van, D. Schacht, A. M. Picquet, M. Garraud et al., Gender-dependent specific immune response during chronic human Schistosomiasis haematobia, Clin Exp Immunol, vol.124, issue.1, p.1906031, 2001.

F. Mutapi, T. Mduluza, N. Gomez-escobar, W. F. Gregory, C. Fernandez et al., Immuno-epidemiology of human Schistosoma haematobium infection: preferential IgG3 antibody responsiveness to a recombinant antigen dependent on age and parasite burden, BMC Infect Dis, vol.6, p.1523344, 2006.

H. Gascan, J. F. Gauchat, M. G. Roncarolo, H. Yssel, H. Spits et al., Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones, J Exp Med, vol.173, issue.3, p.2118815, 1991.

M. Santini-oliveira, R. N. Coler, J. Parra, V. Veloso, L. Jayashankar et al., Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults, Vaccine, vol.34, issue.4, p.26571311, 2016.

J. M. Grzych, D. Bont, J. Liu, J. Neyrinck, J. L. Fontaine et al., Relationship of impairment of schistosome 28-kilodalton glutathione S-transferase (GST) activity to expression of immunity to Schistosoma mattheei in calves vaccinated with recombinant Schistosoma bovis 28-kilodalton GST, Infect Immun, vol.66, issue.3, p.108027, 1998.

L. K. James and S. J. Till, Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions, Curr Allergy Asthma Rep, vol.16, issue.3, p.4759210, 2016.